Validation of a commercially available SARS-CoV-2 serological Immunoassay

Benjamin Meyer, Giulia Torriani, Sabine Yerly, Lena Mazza, Adrien Calame, Isabelle Arm-Vernez, Gert Zimmer, Thomas Agoritsas, Jérôme Stirnemann, Hervé Spechbach, Idris Guessous, Silvia Stringhini, Jérôme Pugin, Pascale Roux-Lombard, Lionel Fontao, Claire-Anne Siegrist, Isabella Eckerle, Nicolas Vuilleumier, Laurent Kaiser, for the Geneva Center for Emerging Viral Diseases
doi: https://doi.org/10.1101/2020.05.02.20080879

Article Information

doi 
https://doi.org/10.1101/2020.05.02.20080879
History 
  • May 6, 2020.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.

Author Information

  1. Benjamin Meyer#,1,
  2. Giulia Torriani#,2,
  3. Sabine Yerly3,
  4. Lena Mazza3,
  5. Adrien Calame4,
  6. Isabelle Arm-Vernez3,
  7. Gert Zimmer5,6,
  8. Thomas Agoritsas7,8,
  9. Jérôme Stirnemann7,
  10. Hervé Spechbach9,
  11. Idris Guessous9,
  12. Silvia Stringhini9,10,
  13. Jérôme Pugin11,
  14. Pascale Roux-Lombard12,
  15. Lionel Fontao13,
  16. Claire-Anne Siegrist1,
  17. Isabella Eckerle2,4,14,
  18. Nicolas Vuilleumier*,#,12,15,
  19. Laurent Kaiser*,#,3,4,14,
  20. for the Geneva Center for Emerging Viral Diseases
  1. 1Centre for Vaccinology, Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland
  2. 2Department of Microbiology and Molecular Medicine, University of Geneva, Geneva, Switzerland
  3. 3Laboratory of Virology, Geneva University Hospitals, Geneva, Switzerland
  4. 4Division of Infectious Disease, Geneva University Hospitals, Geneva, Switzerland
  5. 5Institute of Virology and Immunology (IVI), Mittelhäusern, Switzerland
  6. 6Department of Infectious Diseases and Pathobiology (DIP), Vetsuisse Faculty, University of Bern, Bern, Switzerland
  7. 7Division of General Internal Medicine, Department of Medicine, Geneva University Hospitals, Geneva, Switzerland
  8. 8Department of Health Research Methods, Evidence, and Impact, Hamilton, Ontario, Canada
  9. 9Division and Department of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland
  10. 10Unit of Population Epidemiology, Division of Primary Care, Geneva University Hospitals, Geneva, Switzerland
  11. 11Division of Intensive Care, Geneva University Hospitals, Geneva, Switzerland
  12. 12Division of Laboratory Medicine, Department of Diagnostics, Geneva University Hospitals and Geneva University, Geneva, Switzerland
  13. 13Division of Dermatology and of Laboratory Medicine, Geneva University Hospitals, Geneva, Switzerland
  14. 14Geneva Centre for Emerging Viral Diseases, Geneva University Hospitals, Geneva, Switzerland
  15. 15Division of Laboratory Medicine, Department of Medicine, Faculty of Medicine, Geneva, Switzerland
  1. ↵*corresponding authors: Address for correspondence: Laurent Kaiser: Laurent.Kaiser{at}hcuge.ch, Nicolas Vuilleumier: Nicolas.Vuilleumier{at}hcuge.ch

  1. ↵# contributed equally

Back to top
Posted May 06, 2020.
Download PDF
Data/Code
Email
Validation of a commercially available SARS-CoV-2 serological Immunoassay
Benjamin Meyer, Giulia Torriani, Sabine Yerly, Lena Mazza, Adrien Calame, Isabelle Arm-Vernez, Gert Zimmer, Thomas Agoritsas, Jérôme Stirnemann, Hervé Spechbach, Idris Guessous, Silvia Stringhini, Jérôme Pugin, Pascale Roux-Lombard, Lionel Fontao, Claire-Anne Siegrist, Isabella Eckerle, Nicolas Vuilleumier, Laurent Kaiser, for the Geneva Center for Emerging Viral Diseases
medRxiv 2020.05.02.20080879; doi: https://doi.org/10.1101/2020.05.02.20080879
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area